Anlon Healthcare Limited (AHCL)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 consolidated revenue 105.61 Cr (+102.3% y-y), EBITDA 25.24 Cr (+84.1%), PAT 17.18 Cr (+84.4%)
- H1 FY27 revenue 193.17 Cr (+125.9%), EBITDA 40.83 Cr (+104.7%, margin 21.1%), PAT 25.46 Cr (+97.9%)
- FY27 revenue guidance INR 380-400 Cr; FY28 guidance INR 650-700 Cr
- EBITDA margin recovering to 23.9% in Q2; expected sustainable range 25-28%
- Capacity expansion on track: 1,200 MTPA at Rajkot by Q1 FY28; Apiqo 500-600 MTPA by Q1 FY28
- CDMO commercial supply delayed; first molecule expected Q4 FY27; others post H1 FY28
- Medical devices revenue expected from Q3 FY28; EBITDA margin above 25% anticipated
- Working capital cycle improved; operating cash flow positive expected by FY27 end
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AHCL — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AHCL to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Anlon Healthcare Limited
Important.
The summary above is generated automatically from Anlon Healthcare Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.